4Q’14 & 2014 Earnings Call

Supplemental Slides

March 2, 2015

4Q’14 & 2014 Financial Highlights

1

4Q’13 4Q’14 % Change 2013 2014 % Change

Revenue $412m $612m +49% $1.5b $2.2b +46%

Total prescriptions

dispensed188,000 208,000 +11% 722,000 797,000 +10%

Gross margins 6.1% 6.7% 60 bps 5.9% 6.3% 40 bps

Adjusted EBITDA $5.8m $10.5m +81% $19.0m $35.2m +85%

Quarterly Results Annual Results

2

Fourth Quarter Results

(1) Based on dispensed prescriptions only.(2) Gross profit / net sales (i.e., based on dispensed and serviced prescriptions).

$412

$612

4Q13A 4Q14A

Revenue

EBITDAmargin

1.4%

$5.8

$10.5

4Q13A 4Q14A

Adjusted EBITDA

$126

$187

4Q13A 4Q14A

Gross Profit /Prescription($ in millions) ($ in millions)

1.7%6.7%6.1%

(1)

Grossmargin

(2)

3

Balance sheet snapshot

2013($ in millions)

Cash $9

Total debt $88

2014

$18

–

December 31,

* Includes a $63M draw on a $120M revolving line of credit

*

2015 Guidance

4

2014 Results 2015 GuidanceImplied

Midpoint Growth

Revenue $2.2b$2.8b - $3.1b

*Includes $150-200M

from 9 months of BioRx

+34%

Adjusted EBITDA $35.2m$63m - $67m*Includes $18-20M

from 9 months of BioRx

+85%

*Assuming a March 31, 2015 close

BioRx Transaction Review

Announced February 26, 2015

Transaction Summary

6

Target

Purchase Price

Consideration

Management

Anticipated Closing

• BioRx, LLC

• Specialty pharmacy and infusion services company that provides treatments for patients with ultra-orphan

and rare, chronic diseases based in Cincinnati, Ohio

• 2014 revenue of ~$227 million and EBITDA of ~$23 million

• $315 million gross purchase price

• $265 million adjusted purchase price

- Net of future tax benefit of approximately $50 million

- Represents ~11.5x trailing CY 2014 EBITDA

• One year contingent earnout of additional $35 million in DPLO stock subject to an EBITDA-based target

• $210 million in cash

- Committed financing provided by GE Capital

• $105 million in stock, representing ~4 million shares

- Pro forma ownership of ~7% (pre-earnout)

• Expected to be accretive to EPS in first full year post-close

• BioRx co-founders have made multi-year commitments to help lead the Diplomat specialty infusion

organization

• The transaction is anticipated to close in the next 30-60 days

• Subject to regulatory approvals and other customary closing conditions

Strong Strategic Value For Diplomat

7

• Benefits Diplomat’s primary constituents:

- Broadens patient offerings

- Meets Pharma’s demand for multi-channel reach

- Addresses Payors’ desires to shift site of care to a lower cost setting

• Adds significant scale to our specialty infusion business

- Diplomat is now one of the nation’s top specialty infusion providers

• Provides ability to compete for national contracts

• Offers both revenue and cost synergies

• Increases exposure to higher margin businesses

• Potential for addition of new disease states & therapeutic categories

• Founded in 2004

• Unique additional

limited distribution drugs

• Focuses on treating small

patient populations with rare

diseases, which typically have

complex treatment protocols at high costs, similar to Diplomat

• Pure specialty & nutrition portfolio with strong immuno-therapy

volume

BioRx Snapshot

$0

$50

$100

$150

$200

$250 Revenue History

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

8